Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
2025 · 2nd Quarter (Apr 1 - June 30)
ASTELLAS PHARMA US, INC.
Filed by TIBER CREEK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK GROUP
- Client
- ASTELLAS PHARMA US, INC.
- Filing UUID
- 2807c13e-dee1-4914-81a5-30952996e879
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to oncology; Issues related to ophthalmology; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.